Systemic sclerosis & Raynaud's
Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group
Authors' conclusion
The incidence of COVID-19 infection was higher in AHSCT-SSc compared to non-AHSCT SSc patients, with no difference in vaccine acceptance rate.
Study context
- Population
- Systemic sclerosis (SSc) patients eligible for SARS-CoV-2 vaccination, France1:1 matched
- Participants
- 72 patients
- Comparison
- Autologous Haematopoietic Stem Cell Transplantation (AHSCT)-treated SSc vs non-AHSCT SSc
- AHSCTn = 36
- non-AHSCTn = 36reference
- Outcome
- Cumulative incidence of COVID-19 infection
Methodological detailsmatched 1:1 on age, sex and disease duration, French
- Matched 1:1 on age, sex and disease duration
- French
Main finding
As reported in the abstract
COVID-19 infection (mild to moderate)
AHSCT
11
events
non-AHSCT
2
events
P = 0.007
Observational data: associations, not effects.
Secondary outcomes
Events
| Outcome | AHSCT | non-AHSCT |
|---|---|---|
| Vaccination refusal | 5 | 3 |
Vaccination refusal
- Vaccine acceptance rate did not differ between groups
Serological response
- Serological responses did not significantly differ between the two groups
Safety
Severe adverse events after SARS-CoV-2 vaccination
- None reported
- 0
Original publication
Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group. Clin Exp Rheumatol. Published 15 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →